Sanofi (NASDAQ:SNY) Shares Purchased by National Bank of Canada FI

National Bank of Canada FI boosted its stake in shares of Sanofi (NASDAQ:SNY) by 2.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 303,934 shares of the company’s stock after buying an additional 6,089 shares during the period. National Bank of Canada FI’s holdings in Sanofi were worth $14,659,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of SNY. Abel Hall LLC increased its stake in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after acquiring an additional 194 shares during the last quarter. Providence Capital Advisors LLC increased its position in shares of Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company’s stock worth $2,653,000 after purchasing an additional 201 shares during the last quarter. Keudell Morrison Wealth Management raised its holdings in Sanofi by 1.7% in the 4th quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock valued at $624,000 after buying an additional 217 shares during the period. Bailard Inc. lifted its position in Sanofi by 1.4% in the fourth quarter. Bailard Inc. now owns 16,359 shares of the company’s stock valued at $789,000 after buying an additional 220 shares during the last quarter. Finally, Old Port Advisors increased its position in shares of Sanofi by 0.6% during the fourth quarter. Old Port Advisors now owns 36,704 shares of the company’s stock valued at $1,770,000 after acquiring an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 4.8 %

Shares of NASDAQ SNY opened at $51.98 on Friday. The stock has a market cap of $131.92 billion, a P/E ratio of 20.88, a PEG ratio of 1.01 and a beta of 0.57. The business’s fifty day simple moving average is $55.37 and its 200-day simple moving average is $52.71. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, equities analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SNY shares. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.